Apixaban and Cangrelor: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Apixaban
Cangrelor
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Apixaban (Eliquis) is a blood thinner that helps stop dangerous clots. Cangrelor (Kengreal) is an antiplatelet medicine given in the hospital that keeps platelets from sticking together. Both work to prevent clotting, just in different ways. When you take them together, their effects add up, so your risk of bleeding goes up too.
This isn't a reason to panic. Doctors sometimes use these together on purpose and watch you closely. Just be alert for signs of bleeding, such as unusual bruising, pink or red urine, black stools, bleeding gums, or feeling dizzy. If you notice any of these, tell your care team right away or go to the emergency room. Your team can manage this safely.
Mechanism: additive pharmacodynamic effect on hemostasis. Apixaban is a direct factor Xa inhibitor; cangrelor is an IV reversible P2Y12 platelet inhibitor. Neither is a prodrug (cangrelor is directly active, unlike clopidogrel), so this is straightforward additive antithrombotic effect, increasing bleeding risk.
- Direction: increased bleeding risk (increased combined antithrombotic effect).
- Severity/evidence: major; theoretical/additive basis.
- Management: assess necessity of concurrent use; monitor for bleeding; evaluate any signs of blood loss promptly. Discontinue apixaban with active pathological hemorrhage.
- Reversal: andexanet alfa reverses anti-FXa activity; apixaban effect persists ~24h. PCC/aPCC/rFVIIa may be considered. During PCC use, PT/INR/aPTT/anti-FXa monitoring is not useful. Oral activated charcoal reduces apixaban absorption.
What happens
Increased risk of bleeding and can cause serious, potentially fatal bleeding
Interaction Deep Dive
The combined use of apixaban with antiplatelet medications raises bleeding risk1. In a patient receiving both anticoagulants and antiplatelet drugs at the same time, any indication of blood loss should be assessed without delay 2. Apixaban should be stopped in patients experiencing active pathological hemorrhage. Patients should be informed about the signs and symptoms of blood loss and instructed to report them immediately or seek emergency care. In cases of active pathological hemorrhage, apixaban should be discontinued. A reversal agent for the anti-factor Xa activity of apixaban exists. Apixaban's pharmacodynamic effect is anticipated to remain for a minimum of 24 hours following the final dose. Options that may be considered include prothrombin complex concentrate (PCC), activated prothrombin complex concentrate, or recombinant factor VIIa. If PCCs are administered, it is neither helpful nor advised to monitor apixaban's anticoagulant effect through a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity. Absorption of apixaban is diminished by activated oral charcoal, which consequently reduces apixaban plasma concentration 1.
Why it happens (mechanism)
Additive effects on hemostasis
How to manage this interaction
If your care team has prescribed both, keep taking them exactly as directed. This combination is sometimes used intentionally, and your team can manage it by watching you closely.
- Know the warning signs of bleeding: unusual or heavy bruising, blood in urine or stool, black tarry stools, nosebleeds or bleeding gums that won't stop, coughing or vomiting blood, severe headache, or unusual weakness or dizziness.
- Report these right away to your pharmacist or prescriber, or go to an emergency room.
- Do not start or stop either drug on your own. Any dose changes should be individualized by your care team.
- Tell every provider you see that you take both, especially before any procedure or surgery.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
3 reports — tap to read
a) A clinical study involving high-risk patients following acute coronary syndrome who were treated with aspirin or with aspirin plus clopidogrel (APPRAISE-2) was halted prematurely because apixaban produced a greater bleeding rate than placebo. Among patients on single antiplatelet therapy, the rate of ISTH major bleeding was 2.8% per year with apixaban compared with 0.6% per year with placebo, and among those on dual antiplatelet therapy it was 5.9% per year with apixaban compared with 2.5% per year with placebo 1.
b) Among patients treated with apixaban, adding aspirin raised the annual bleeding risk from 1.8% to 3.4%, and adding both aspirin and warfarin raised it from 2.7% per year to 4.6% per year in a clinical study (ARISTOTLE); use of dual antiplatelet therapy alongside apixaban in this trial was limited (2.3%) 1.
c) In a retrospective study, combining direct oral anticoagulant (DOAC) therapy with antiplatelet therapy (APT; n=78), compared with DOAC therapy alone (n=329), did not meaningfully change the rate of major bleeding (1.3% vs 1.2%) or clinically relevant non-major bleeding (10.2% vs 6.4%) across 6 months of treatment. The patients were mainly Caucasian men with an average age of 63.7 years. Those given concurrent APT had a significantly greater mean body mass index (30.7 vs 28.4), a higher mean CHA2DS2-VASc score (4.28 vs 3.85), and were more often diabetic (26.9% vs 17.3%) than those on DOAC monotherapy. DOACs were used for VTE treatment or atrial fibrillation and comprised apixaban (58.5%), rivaroxaban (38.1%), and dabigatran (3.4%). Single antiplatelet therapy was employed in 94.9% (74 patients), with aspirin 81 mg once daily being the most frequent regimen (69 patients). Additional APT regimens were aspirin 81 mg twice daily (3 patients), aspirin 325 mg daily (1 patient), clopidogrel 75 mg daily (1 patient), and dual APT with aspirin 81 mg and clopidogrel 75 mg daily (4 patients) 3.
Common questions
Can I take Apixaban and Cangrelor together?
Taking apixaban with cangrelor adds up their clot-preventing effects and raises your bleeding risk, so watch closely for signs of bleeding and report them immediately. Keep taking both as prescribed and let your care team manage it. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Cangrelor interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Cangrelor interaction managed?
If your care team has prescribed both, keep taking them exactly as directed. This combination is sometimes used intentionally, and your team can manage it by watching you closely. Know the warning signs of bleeding: unusual or heavy bruising, blood in urine or stool, black tarry stools, nosebleeds or bleeding gums that won't stop, coughing or vomiting blood, severe headache, or unusual weakness or… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Cangrelor need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (3)
- Product Information: ELIQUIS(R) oral film coated tablets, apixaban oral film coated tablets. Bristol-Myers Squibb Company (per Dailymed), Princeton, NJ, 2024. DailyMed
- Product Information: SAVAYSA(R) oral tablets, edoxaban oral tablets. Daiichi Sankyo Inc (per FDA), Basking Ridge, NJ, 2023. DailyMed
- Tinkham TT, Vazquez SR, Jones AE, et al: Direct oral anticoagulant plus antiplatelet therapy: prescribing practices and bleeding outcomes. J Thromb Thrombolysis 2020; 49(3):492-496. PubMed
Keep reading about Apixaban
Keep reading about Cangrelor
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist